Clinical Trials Logo

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate toxicity and estimate the maximum tolerated dose (MTD) of melphalan (intra-arterially [i.a.]) administered in conjunction with carboplatin (i.a.) and etoposide phosphate (intravenously [i.v.]) undergoing BBBD, in subjects with anaplastic oligodendroglioma or oligoastrocytoma. (Phase I) II. To examine the efficacy (one year progression free survival [1YPFS]) of carboplatin (i.a.), melphalan (i.a.) and etoposide phosphate (i.v.) in conjunction with BBBD, in subjects with anaplastic oligodendroglioma or oligoastrocytoma. (Phase II) SECONDARY OBJECTIVES: I. To evaluate the incidence of severe neutropenia (specifically febrile neutropenia or sepsis) of carboplatin (i.a.), melphalan (i.a.) and etoposide phosphate (i.v.) in conjunction with BBBD, in subjects with anaplastic oligodendroglioma or oligoastrocytoma. II. To evaluate the overall toxicity of carboplatin (i.a.), melphalan (i.a.), and etoposide phosphate (i.v.) in conjunction with BBBD. III. To estimate the differences in tumor response, 1YPFS and survival, in subjects with allelic loss of chromosomes 1p and 19q, and tumor protein p53 (p53) immunocytochemistry, versus subjects without allelic loss. IV. To assess quality of life, cognitive function, and performance status of subjects undergoing treatment with carboplatin, melphalan and etoposide phosphate in conjunction with BBBD. V. To estimate differences in 1YPFS between subjects with anaplastic oligodendroglioma and patients with oligoastrocytoma. VI. To describe the role of biopsy versus extent of surgery (sub-maximal versus maximal safe resection) on 1YPFS and survival. VII. To describe the role of prior radiation on tumor response, 1YPFS and survival. OUTLINE: This is a phase I, dose-escalation study of melphalan followed by a phase II study. Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months. After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00303849
Study type Interventional
Source OHSU Knight Cancer Institute
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 15, 2005
Completion date March 12, 2021

See also
  Status Clinical Trial Phase
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Completed NCT00390299 - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1
Completed NCT03043391 - Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Phase 1
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Completed NCT02644291 - Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Phase 1
Completed NCT01847235 - Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Phase 2
Completed NCT01380782 - BIBF 1120 for Recurrent High-Grade Gliomas Phase 2
Completed NCT01082926 - Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Phase 1
Completed NCT00362570 - Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Phase 2
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Completed NCT01316809 - AZD8055 for Adults With Recurrent Gliomas Phase 1
Recruiting NCT04135807 - Implantable Microdevice In Primary Brain Tumors Early Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Completed NCT00884416 - Sorafenib in Newly Diagnosed High Grade Glioma Phase 1
Active, not recruiting NCT02101905 - Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Phase 1
Recruiting NCT05698524 - A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma Phase 1
Recruiting NCT01637753 - Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma N/A
Withdrawn NCT00734864 - Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Phase 1